Balchem Co. (NASDAQ:BCPC - Get Free Report) shares dropped 86.1% during trading on Monday . The stock traded as low as $164.50 and last traded at $23.14. Approximately 11,386 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 138,016 shares. The stock had previously closed at $166.70.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. HC Wainwright set a $180.00 price target on shares of Balchem and gave the stock a "buy" rating in a research report on Monday, April 28th. Sidoti raised shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. Finally, Wall Street Zen cut shares of Balchem from a "buy" rating to a "hold" rating in a research report on Wednesday, May 21st.
Get Our Latest Report on Balchem
Balchem Stock Performance
The firm has a market cap of $5.42 billion, a price-to-earnings ratio of 42.31, a price-to-earnings-growth ratio of 4.41 and a beta of 0.93. The stock's 50 day moving average is $162.19 and its 200 day moving average is $165.59. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.19.
Balchem (NASDAQ:BCPC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). The firm had revenue of $250.52 million for the quarter, compared to analyst estimates of $245.70 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. The business's revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.03 EPS. Analysts anticipate that Balchem Co. will post 4.64 earnings per share for the current year.
Institutional Trading of Balchem
Several large investors have recently made changes to their positions in BCPC. Norges Bank acquired a new stake in shares of Balchem during the 4th quarter worth approximately $70,165,000. Nuveen LLC acquired a new stake in Balchem in the first quarter valued at approximately $47,214,000. GAMMA Investing LLC boosted its position in Balchem by 20,231.2% in the first quarter. GAMMA Investing LLC now owns 177,288 shares of the basic materials company's stock valued at $29,430,000 after buying an additional 176,416 shares in the last quarter. Millennium Management LLC boosted its position in Balchem by 660.5% in the first quarter. Millennium Management LLC now owns 195,525 shares of the basic materials company's stock valued at $32,457,000 after buying an additional 169,816 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in Balchem in the fourth quarter valued at approximately $23,628,000. Institutional investors and hedge funds own 87.91% of the company's stock.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Further Reading
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
